Sign Up NowThis Month's Tiny Gems - April 2017

Bollente Companies, Inc. (BOLC)
CytoDyn Inc. (CYDY)
eXp World Holdings, Inc. (EXPI)
Grey Cloak Tech, Inc. (GRCK)
India Globalization Capital, Inc. (NYSE: IGC)
InMed Pharmaceuticals, Inc. (IMLFF)
Moxian, Inc. (NASDAQ: MOXC)
National Waste Management Holdings Inc. (NWMH)
Net Element (NASDAQ: NETE)
ORHub, Inc. (ORHB)
ProBility Media Corp. (PBYA)
SolarWindow Technologies, Inc. (WNDW)
Stealth Technologies Inc. (STTH)
TapImmune, Inc. (NASDAQ: TPIV)

 

 

 

Bollente Companies, Inc. (BOLC)

 

Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.

 

The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.

 

The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.

 

By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.

 

Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.

 

Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers.

 

 

 

CytoDyn Inc. (CYDY)

 

CytoDyn Inc. (CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection.

 

Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn's lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.

 

PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral infection. The candidate has been used in more than 200 HIV-infected patients in placebo-controlled and open label FDA-approved clinical trials; has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and is designated a "fast track" product candidate by the FDA.

 

The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially hardly any side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use. CytoDyn has received FDA clearance for and currently has two Phase 3 clinical trials underway. The company's first Phase 3 trial is a pivotal trial with PRO 140 in combination with current standard-of-care antiretroviral therapy (ART) for highly treatment-experienced patients with HIV. This 25-week trial involves only 30 patients with a primary endpoint of just one week of efficacy and the company expects to report primary endpoint results as early as the first quarter of 2017.

 

The company's other Phase 3 trial is with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. This multicenter, open-label trial is now enrolling 300 patients prequalified with CCR5-tropic HIV-1 infection who are clinically stable on standard-of-care highly active antiretroviral therapy (HAART). The objective of the trial is to assess the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Patients enrolled in the trial will be shifted from daily HAART regimens to weekly PRO 140 subcutaneous injections for 48 weeks. This trial protocol is nearly a duplicate of the Phase 2b monotherapy trial, which is ongoing with an extension study that supports a group of patients who have maintained viral suppression for over two years and is continuing.

 

Additionally, the company has underway a Phase 2 trial to evaluate PRO 140 for Graft vs. Host Disease (GvHD) in a 100-day study involving 60 patients. GvHD is a life-threatening complication for cancer patients undergoing stem cell transplants. This trial will evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem-cell transplantation.

 

CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more. Additionally, CytoDyn has established relationships with world-class HIV experts who advise on the company's trial designs.

 

 

 

eXp World Holdings, Inc. (EXPI)

 

eXp World Holdings, Inc. (EXPI) is the holding company for several entities, the most recognizable of which is eXp Realty LLC, the Agent-Owned Cloud Brokerage® full-service real estate brokerage. Since its inception in 2009, eXp Realty has focused on becoming the first agent-owned, full-service, global real estate brokerage company to deliver 24/7 access to collaborative tools, socialization, and professional development in a cloud-based environment.

 

As a cloud-based real estate brokerage, eXp Realty utilizes a number of cutting-edge technologies in order to grow an international brokerage without the various burdens of maintaining physical brick-and-mortar offices and staffing costs.

 

Utilizing cloud technologies and the Internet, eXp Realty's online community of real estate professionals operate within a 3D, fully immersive business model that enables them to increase listings and sales while reducing overhead and capital requirements.

 

The unique nature of this structure continues to gain acceptance and traction among industry professionals, and as of August 2016, the company's brokerage agent base topped 1,630 real estate professionals – up from 864 at the beginning of the year. This rapid growth helped the Agent-Owned Cloud Brokerage claim a spot among the Top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.

 

eXp Realty and eXp Realty of Canada, Inc. also offer agents and brokers an aggressive revenue sharing program that pays them a percentage of gross commission income earned by fellow real estate professionals who they refer into the company. This structure creates a truly agent-owned community of forward-thinking, entrepreneurial professionals.

 

eXp Realty is notching considerable growth in the marketing and sale of residential real estate, and now offers its brokerage service in 41 U.S. states, the District of Columbia, as well as Alberta, Canada. Leveraging its growing market presence, powered by the marketing reach of the Internet, eXp Realty has helped thousands of consumers find, buy or sell homes without ever stepping foot into a traditional real estate office.

 

 

 

Grey Cloak Tech, Inc. (GRCK)

 

Grey Cloak Tech, Inc. (GRCK) is a developer of industry-leading click-fraud detection software designed to overcome the most expensive and devastating threats in the digital world. Through its recently acquired subsidiary, ShareRails, Grey Cloak now also provides sophisticated e-commerce tools that help retailers evolve beyond their brick-and-mortar business practices to increase both their digital engagement and their foot traffic.

 

ShareRails is an online-to-offline technology firm that provides vitally important services within the trillion-dollar retail sector, helping brick-and-mortar retailers compete directly for online awareness with e-commerce-only brands. Through the ShareRails O2O platform, offline retailers can use online channels to more effectively drive sales and attract new customers.

 

The innovative solutions offered by ShareRails enable local retailers to capture the millions of online shopping searches they are currently missing out on because their product inventories and other key information is not currently available online and, therefore, does not appear in relevant searches and cannot be viewed digitally.

 

Most of today's retail sales are Web-influenced. By utilizing digital marketing channels, merchants can enhance the in-store shopping experience for customers and simultaneously boost sales. The ShareRails O2O platform enables retailers to put their product catalogs online, along with product location and availability, and make the information searchable. The platform also offers digital merchandising tools that include an outfit builder and wishlist app along with conversational shopping tools. Through ShareRails O2O, merchants can additionally tap into data that details shopper insights and behavioral trends. Add-on services include click-n-collect, reservations for in-store pickup, and local delivery.

 

ShareRails additionally offers Dress.li, which is a recommendation and reward platform that connects shoppers to stylists, bloggers and other fashion influencers who provide them with expert shopping advice and uniquely styled looks and, simultaneously, connects the consumers to fashion retailers. Through Dress.li, the challenge of creating a seamless social shopping experience has finally been mastered! This platform facilitates live shopping communications, curation and content creation and lets users join a global network of trendsetters. Through this network, users can inspire and be inspired, accessing and sharing product recommendations and unique looks and receiving rewards each time another user makes a purchase from their recommendations. This platform not only provides an enjoyable and exciting network for shoppers and fashionistas, but it simultaneously supplies retailers with a lucrative outlet for acquiring new customers through a built-in global sales force of fashion influencers. As these Dress.li stylists create and share looks, they also deliver pre-qualified sales leads and conversions and are rewarded for doing so.

 

Joined together, Grey Cloak Tech's industry-leading click-fraud detection solutions and the exciting retail-boosting products delivered through ShareRails offer a broad package of services to both protect businesses in the digital world and help them utilize digital channels to bolster their sales and enhance customer engagement.

 

Grey Cloak Tech continues to serve as an industry leader in developing the most effective and comprehensive weapons to fight online security threats. The company is keenly focused on protecting its clients' interests through the identification of fraud patterns at the very earliest stages. When businesses partner with Grey Cloak Tech, they can look forward to benefiting from industry-leading technology, a top-tier client services team, and an augmented bottom line.

 

 

 

India Globalization Capital, Inc. (NYSE: IGC)

 

India Globalization Capital, Inc. (NYSE: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

 

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

 

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

 

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

 

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

 

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

 

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings.

 

 

 

InMed Pharmaceuticals, Inc. (IMLFF)

 

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company's cannabinoid biosynthesis technology and drug development pipeline, serves as InMed's fundamental value driver.

 

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed's website, this type of bioinformatics assessment represents "significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease."

 

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company's proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

 

The company's pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

 

INM-085, InMed's second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

 

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

 

The company's management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

 

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

 

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company's current market value totaling more than $2.9 billion.

 

 

 

 

Moxian, Inc. (NASDAQ: MOXC)

 

Moxian, Inc. (NASDAQ: MOXC) is a leading offline-to-online (O2O) integrated platform operator committed to providing high-quality social marketing and promotion platforms to end-users and merchants interested in promoting their business via social media.

 

The company's proprietary Social Customer Relationship Management (Social CRM) system is at the foundation of its multi-channel social commerce platform, and was developed to foster enhanced consumer/merchant interaction. By integrating social media, entertainment and business intelligence, Moxian's system is especially suitable for SMB, integrated entertainment, commerce, shopping and customer loyalty rewards providers.

 

Through its big data analytics system, Moxian has a clear picture of its targeted customers, their demands and payment data. End-user data generated from the platform helps Moxian's merchant clients achieve optimal marketing strategies.

 

Leveraging these assets, Moxian has two primary core products: Moxian User App and Moxian Business App.

 

The structure of Moxian User APP is for consumers to collect loyalty points from issuing merchants. Virtual currency (MO-Coin and MO-Points) is earned playing games and can be redeemed globally with any merchant in Moxian eco-system. This model drives registered consumers to Moxian and its merchant clients while providing merchants the opportunity to advertise, run marketing campaigns, and learn about their customers through Moxian's platform. The app also provides consumers a set of social networking features to set up a personalized multimedia profile and participate in traditional social media functions such as friend search, interest groups, topics and content sharing.

 

Moxian Business App is similar in that it is also based on loyalty points, but is geared toward the merchant. This app provides merchants the tool kits to covert customers into members and fans, issue loyalty points and redeem rewards, and respond to customer inquiries via instant messaging. Users can also conduct targeted marketing campaigns to members of Moxian community in the form of ads and games, list products online, as well as process orders. Moxian Business also provides business reports and analytical insights for merchants.

 

Led by a management team with more than a century of combined experience, Moxian's technologies supplement the company's broader corporate mission to create and lead a personalized social network platform best suited for modern users and businesses.

 

 

 

National Waste Management Holdings Inc. (NWMH)

 

National Waste Management Holdings Inc. (NWMH) is a growing solid waste management company serving Florida's west coast and upstate New York with comprehensive solutions for full waste diversion. The company's current operations center on its 54-acre landfill facility located in Hernando, Florida, which handles average disposals of roughly 240,000 cubic yards of construction debris each year and is already permitted for future expansion. National Waste also offers ancillary services, such as roll-off dumpster services, recycling and retail mulching services.

 

Leveraging a number of long-term partnerships with municipal, institutional, commercial and industrial customers, National Waste aims to position itself as a leading waste diversion company in the coming years. In support of this goal, National Waste has already completed multiple acquisitions designed to enhance its geographic footprint and overall market share, and management has confirmed that additional acquisition targets are currently on the company's radar.

 

Through the acquisition of Waste Recovery Enterprises, LLC in New York, National Waste gained a foothold in the Northeast and the capacity to serve both the industrial and residential markets with waste processing and disposal, as well as recycling services. On the other hand, the acquisition of Gateway Rolloff Services, one of the largest roll-off/dumpster company in Central Florida, positioned National Waste as the leading full-service provider of construction and demolition landfill operations in the region. The two acquisitions are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward.

 

Outside of its roll-up M&A strategy, the company is also looking at expanding its reach by opening new satellite offices in counties and states that neighbor its existing operations while maintaining an emphasis on improving operational efficiency and maximizing shareholder value.

 

Current trends within the domestic waste management industry support National Waste's aggressive strategy. According to IBISWorld, the U.S. solid waste treatment and disposal services industry generated approximately $18.8 billion in 2014, and the industry is projected to record a compound annual growth rate of 9.67 percent throughout the five-year period ending in 2019. This market performance will likely be bolstered by the ongoing rally in the domestic construction and demolition markets.

 

National Waste's existing working relationships with Florida's Department of Environmental Protection and the considerable industry experience of its management team allow it to capably navigate the complex regulatory environment of the waste management industry. Meanwhile, the same regulations and required certifications combine to create significant capital requirements and serve as major barriers of entry that effectively limit new and emerging competition in the space.

 

 

 

Net Element (NASDAQ: NETE)

 

Net Element (NASDAQ: NETE) is a global technology company delivering a range of electronic payment solutions that enable merchants of all sizes to process transactions through various integrated platforms. Ranked as one of South Florida Business Journal's Top 25 Fastest-Growing Technology Companies, Net Element bases its products around a set of innovations that enables it to compete in select, competitive market segments.

 

Florida-based Net Element owns and operates a global mobile payments and transactional processing provider TOT Group, Inc., parent company to: Unified Payments, which was recognized by Inc. Magazine as the #1 Fastest Growing Company in America in 2012; Aptito, a next generation cloud-based point-of-sale ("POS") payments platform; Restoactive, a seamless digital add-ons for legacy POS systems; Digital Provider, a leading provider of SMS messaging and mobile billing solutions; and Payonline, a fully integrated processor agnostic electronic commerce platform.

 

Revenues are primarily driven by transaction fees, and the company continues to see increased acceptance and adoption of mobile and online payments. In 2015 alone, the company processed 51.2 million bankcard transactions in North America. The same year, Net Element processed 90 million transactions in CIS and the Russian Federation in 2015, as well as 19.5 million mobile transactions in emerging markets.

 

Net Element's domestic strategy is to grow transactional revenue through the innovation of SME productivity services such as its signature POS solution, Aptito. The broader North America market strategy is to expand distribution while exploring new products, services, and value-added offerings.

 

Internationally, Net Element's strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. With a growing physical presence in Central Asia, Net Element has a portfolio of international clients that includes Nokia, Samsonite, Papa Johns, Microsoft, Norton by Symantec, Alawar Entertainment and many others.

 

Laying the groundwork for sustained growth, Net Element continues to focus on improvement and investments in its core technology and new product offerings. The company allocates its resources, along with the extensive experience of its management team, to foster growth in payment processing and the worldwide mobile payment industry, which is forecast to surpass $1 trillion in 2019.

 

 

 

ORHub, Inc. (ORHB)

 

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

 

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

 

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

 

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

 

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

 

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch.

 

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

 

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

 

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care.

 

 

 

ProBility Media Corp. (PBYA)

 

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

 

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

 

Companies currently under the ProBility Media conglomerate include:

 

 

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

 

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries.

 

 

 

SolarWindow Technologies, Inc. (WNDW)

 

SolarWindow Technologies, Inc. (WNDW), based in Columbia, Maryland, is developing the next generation of solar technology that can outperform current solar by as much as 50 times. With 12 times the environmental benefits of current technologies, SolarWindow™ has produced independently validated financial payback within one year, a fraction of the time for conventional approaches. The key to the company's proprietary breakthrough technology is the application of ultra-thin layers of liquid coatings on to glass and flexible plastics, producing ultra-small solar cells and forming groups of Organic Photovoltaic solar arrays (OPV). Notably, the liquid coatings are made primarily of hydrogen and carbon, which are abundant natural elements.

 

The wavelength-sensitive coating allows enough light to pass through to maintain visibility, while still absorbing light energy for the generation of electricity. Once generated in the micro-cells, electricity is transported by a virtually invisible system of ultra-thin conductive wires. The company is also continually working to ensure that the final product appeals to the varied aesthetic demands, as well as financial requirements, of today's industrial and residential markets, including real estate developers, building engineers, and architects. In addition to new construction, coatings are being developed for retrofitting and replacement windows, all while minimizing additional costs to a standard window. Any added costs for electric interconnection are offset by the rapid payback in electrical savings.

 

A major benefit to the technology is its ability to bring highly efficient solar to urban environments, through the company's current development of first-of-a-kind solar windows that allow for direct window-generated electricity in buildings and homes, for which solar would otherwise not be a viable solution. This new generation of solar is engineered to work in even shaded or indoor light, allowing it to be applied successfully to all four sides of tall towers, far exceeding the capabilities of traditional solar. As a result, a tall building that would require 10-12 acres of costly urban land for a typical solar panel field can now generate electricity on all sides using existing windows, dramatically dropping the payback from 5-11 years down to a single year, according to independently validated financial modeling results.

 

SolarWindow Technologies is starting to move from the lab toward final commercialization with the development of a range of SolarWindow™ products, including flat glass products for commercial construction and replacement, window glass for residential construction and replacement, and flexible films for retrofitting existing buildings and homes. Together, these products target America's 85 million detached homes and commercial buildings, with five million commercial buildings in the U.S. alone, a multi-billion dollar market. Approximately 40% of the nation's electricity is consumed by commercial buildings, and most of that electricity comes from greenhouse gas generating fossil-fueled power plants. In a 50-story building, an estimated 30%-50% of that energy could potentially be offset through the use of windows from SolarWindow Technologies.

 

The company envisions its technology as becoming a common part of buildings around the world, providing a source of clean, renewable energy to help meet the world's growing energy demands.

 

 

 

Stealth Technologies Inc. (STTH)

 

Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.

 

The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.

 

StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.

 

The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.

 

Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.

 

Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability.

 

 

 

TapImmune, Inc. (NASDAQ: TPIV)

 

TapImmune, Inc. (NASDAQ: TPIV) is leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms. By fully leveraging the scope of its technology and through collaborative partnerships and license agreements, the company aims to maximize its value and growth potential.

 

Most cancer patients die from metastatic disease, which is when the cancer travels to other parts of the body that ultimately cannot be treated, instead of the primary tumor. TapImmune's immunotherapies overcome the deficiencies of earlier cancer vaccine approaches by targeting both tumors and metastatic diseases. The company's approach further differentiates itself by influencing the body's own immune system to fight the disease.

 

Two clinical stage T-cell vaccine candidates are currently being advanced in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from the FDA Fast Track and Orphan Disease Designation. The U.S. market alone is very large for these cancers, with a combined 290,000 new patients estimated to be diagnosed each year. Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca are among the collaborators in these trials, and the U.S. Department of Defense has provided significant non-dilutive funding as well.

 

The company's off-the-shelf vaccines have been proven to boost patients' immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to treat a wide patient population across varied therapeutic areas of cancer. These vaccines have the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics.

 

PolyStart is TapImmune's unique DNA-based antigen expression system that helps the body recognize and kill target cells. It is a novel vaccine technology platform that creates a four-fold or greater increase in presentation of any antigen, which gives it unlimited application in oncology and infectious disease. The PolyStart platform further solidifies the company as a leader in the development of next-generation vaccines for cancer as it will be able to use this technology for its own vaccine candidates as well as generate additional value for the platform by licensing it to third parties.

 

The company plans to first build value through advancing candidates that treat women's cancers, while continuously developing its unique pipeline. As part of its long-term vision, the company is also developing proprietary technologies that can enhance the potency of DNA-based immunotherapies against other types of cancer and infectious disease. Other goals include discovering, acquiring and developing additional technologies that modulate antigen presentation and driving incremental value by monetizing proprietary protein expression systems through business partnerships.